Dongfeng Qu to Cell Proliferation
This is a "connection" page, showing publications Dongfeng Qu has written about Cell Proliferation.
Connection Strength
0.425
-
Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal. Oncotarget. 2015 Oct 13; 6(31):30876-86.
Score: 0.102
-
Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis. PLoS One. 2015; 10(8):e0134212.
Score: 0.101
-
DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Mol Cancer Ther. 2020 07; 19(7):1539-1549.
Score: 0.035
-
Dclk1 in tuft cells promotes inflammation-driven epithelial restitution and mitigates chronic colitis. Cell Death Differ. 2019 09; 26(9):1656-1669.
Score: 0.032
-
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
Score: 0.030
-
Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury. Sci Rep. 2016 11 23; 6:37667.
Score: 0.027
-
(Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. Cancer Res. 2016 08 15; 76(16):4887-96.
Score: 0.027
-
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget. 2015 Nov 10; 6(35):37200-15.
Score: 0.026
-
XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014 Aug 28; 351(1):151-61.
Score: 0.023
-
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 06; 13:103.
Score: 0.023